Ocular Hypertension
Real-world study shows sustained effect of suprachoroidal triamcinolone in UME
PARK CITY, Utah — Suprachoroidal drug delivery for uveitic macular edema provides durable effects in real-world settings, matching those of phase 3 clinical trials, according to a speaker at Clinical Trials at the Summit.
VIDEO: Triamcinolone acetonide an option in those with uveitic macular edema, IOP issues
In this Healio Video Perspective from the ASRS meeting, Danny Mammo, MD, of Cole Eye Institute discusses the real-world effect of triamcinolone acetonide on IOP in patients with uveitic macular edema.
Novel implants show promise in drug delivery
KIAWAH ISLAND, S.C. — Drug-eluting implants in various stages of study and approval may provide efficient, sustained drug delivery, overcoming barriers to penetration, according to a speaker at Kiawah Eye.
Qlaris raises $24 million for development of IOP-lowering therapy
Qlaris Bio raised $24 million during series B financing for the clinical development of QLS-111, a new IOP-lowering drug candidate for patients with glaucoma, the company announced in a press release.
Sustained-release bimatoprost implant shows safety, efficacy in early study
BOSTON — A sustained-release bimatoprost drug delivery platform shows promise in the treatment of ocular hypertension and open-angle glaucoma, according to a poster at the American Society of Cataract and Refractive Surgery meeting.
Phaco plus MIGS helps improve quality of life, prevent visual field loss
BOSTON — Phacoemulsification plus minimally invasive glaucoma surgery improves quality of life and prevents visual field loss in patients with glaucoma, according to a speaker.
Qlaris Bio initiates trials for potassium channel modulator therapy in glaucoma patients
Qlaris Bio announced the initiation and dosing of two phase 2 trials aimed at assessing QLS-111, a therapy for lowering intraocular pressure by targeting episcleral venous pressure, or EVP, in patients with glaucoma.
Timolol microdrops appear as effective as conventional drops in lowering IOP
Timolol maleate 0.5% microdrops delivered with the Nanodropper Adaptor met three noninferiority endpoints in lowering IOP compared with conventional timolol drops, according to a study.
VIDEO: Iyuzeh reduces risk of inducing dry eye when treating glaucoma
WAILEA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2024, Renee Bovelle, MD, discusses the benefits of using Iyuzeh to treat glaucoma while not inducing dry eye.
Travoprost implant shows ‘robust’ IOP reduction at 3 months
The travoprost intraocular implant demonstrated a reduction in IOP in patients with open-angle glaucoma or ocular hypertension 3 months after a single administration, according to a study published in Ophthalmology.